Bibliography
- NEWTON AC: Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. (2001) 101(8):2353-2364.
- MELLOR H, PARKER PJ: The extended protein kinase C superfamily. Biochem J. (1998) 332(Pt 2):281-292.
- GOEKJIAN PG, JIROUSEK MR: Protein kinase C in the treatment of disease: signal transduction pathways, inhibitors, and agents in development. Curr. Med. Chem. (1999) 6(9):877-903.
- GOEKJIAN PG, JIROUSEK MR: Protein kinase C inhibitors as novel anticancer drugs. Expert Opin. Investig. Drugs (2001) 10(12):2117-2140.
- COHEN P: The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. (1999) 3(4):459-465.
- MCINNES C, FISCHER PM: Strategies for the design of potent and selective kinase inhibitors. Curr. Pharm. Des. (2005) 11(14):1845-1863.
- SHEN GX: Selective protein kinase C inhibitors and their applications. Curr. Drug Targets Cardiovasc. Haematol. Disord. (2003) 3(4):301-307.
- KOBAYASHI E, ANDO K, NAKANO H et al.: Calphostins (UCN-1028), novel and specific inhibitors of protein kinase C. I. Fermentation, isolation, physico-chemical properties and biological activities. J. Antibiot. (Tokyo) (1989) 42(10):1470-1474.
- MOCHLY-ROSEN D: Localization of protein kinases by anchoring proteins: a theme in signal transduction. Science (1995) 268(5208):247-251.
- MOCHLY-ROSEN D, GORDON AS: Anchoring proteins for protein kinase C: a means for isozyme selectivity. Faseb. J. (1998) 12(1):35-42.
- HOOL LC: Protein kinase C isozyme selective peptides-a current view of what they tell us about location and function of isozymes in the heart. Curr. Pharm. Des. (2005) 11(4):549-559.
- WHEELER GD: Ruboxistaurin (Eli Lilly). IDrugs (2003) 6(2):159-163.
- FABBRO D, BUCHDUNGER E, WOOD J et al.: Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. (1999) 82(2-3):293-301.
- JIROUSEK MR, GILLIG JR, GONZALEZ CM et al.: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase Cβ. J. Med. Chem. (1996) 39(14):2664-2671.
- TEICHER BA, ALVAREZ E, MENON K et al.: Antiangiogenic effects of a protein kinase Cβ-selective small molecule. Cancer Chemother. Pharmacol. (2002) 49(1):69-77.
- ADESSI C, SOTO C: Converting a peptide into a drug: strategies to improve stability and bioavailability. Curr. Med. Chem. (2002) 9(9):963-978.
Website
- http://www.kaipharmaceuticals.com/assets/productAcuteMyocardia.html
- http://www.pharmagap.com/cancer.html